Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Chemours Stock Gained 26.7% in January

By Lou Whiteman – Updated Apr 23, 2019 at 11:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors gave the chemicals firm a fresh look after a miserable performance in 2018.

What happened

Shares of specialty chemicals firm Chemours (CC 0.13%) gained 26.7% in January, according to data provided by S&P Global Market Intelligence, on investor sentiment that after a terrible 2018, the company is ready for a rebound.

So what

Chemours, the performance chemicals business that was spun off of the former DuPont (now DowDuPont) in 2015, lost nearly half its value in 2018 as investors reacted to soft global demand for titanium dioxide and the continued push by the Federal Trade Commission (FTC) to block a merger between two of North America's largest producers of that chemical. The industry had hoped the merger would help stabilize prices.

Titanium dioxide, a pigment used in coatings, is the largest business in the Chemours portfolio, which also includes refrigerants, polymer resins, and mining products like sulfuric acid and reactive metals.

Greyscale stock graphic

Image source: Getty Images.

Chemours also has company-specific worries -- lawsuits in North Carolina and elsewhere related to allegations that it allowed chemicals to leak into local drinking water supplies. The company, along with former parent DuPont, had to split a $671 million judgment in 2017 for similar claims in Ohio, and any further judgments against it could tax its balance sheet.

January's rally coincided with a couple of analyst upgrades on the stock, with Wall Street gaining hope that the titanium dioxide market has hit a bottom. Chemours' new Opteon refrigerant, a higher-margin replacement for Freon, is also steadily gaining adoption.

Check out the latest Chemours earnings call transcript.

Now what

It's possible that Chemours was oversold by the end of 2018, but the January rally has taken back much of that discount. And there are still significant headwinds that should give investors concerns. A recovery in the titanium dioxide market seems distant, and the FTC has made it clear the industry will have a hard time consolidating to affect a rebound.

Add in the macroeconomic concerns about a slowing global economy and the litigation risk in North Carolina, and a lot could still go wrong for Chemours.

Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Chemours Stock Quote
$31.05 (0.13%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.